Ivermectin

證據等級: L5

預測適應症: 10 個

Ivermectin: From Parasitic Infections to Vulvovaginal Candidiasis

One-Sentence Summary

Ivermectin is an antiparasitic agent internationally established for conditions such as scabies and strongyloidiasis. The TxGNN model predicts it may be effective for Vulvovaginal Candidiasis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on model similarity scoring alone.

Quick Overview

Item	Content
Original Indication	Parasitic infections (e.g., scabies, strongyloidiasis) — internationally established use; no Danish licence data available, as no marketing authorisation is on file
Predicted New Indication	Vulvovaginal Candidiasis
TxGNN Prediction Score	99.95%
Evidence Level	L5 (model prediction only — no supporting trials or literature)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on generally known pharmacology, ivermectin acts as an agonist at glutamate-gated chloride channels found in invertebrate nerve and muscle cells, which underlies its antiparasitic effect — it has no established mechanistic link to antifungal activity.

Critically, the model-generated rationale for this specific prediction explicitly states that there is no known mechanistic relationship between ivermectin’s antiparasitic action and the ergosterol-synthesis-inhibition or membrane-targeting mechanisms typically involved in treating Candida infections. The prediction appears to be driven by TxGNN embedding similarity rather than any pharmacological or clinical inference.

Given the absence of mechanistic rationale, clinical trials, and literature for this specific candidate, this prediction should be treated as a low-confidence, hypothesis-generating signal only, not as a basis for clinical consideration at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Ivermectin currently holds no marketing authorisation in Denmark (market status: not marketed; 0 licences on file). No product-level information is available for this table.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Note: national warning/contraindication data and drug-drug interaction data could not be retrieved for this evaluation (query status: not found), which blocks a full safety pre-assessment (see Conclusion).

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is supported by no clinical trials and no literature, and the model’s own rationale indicates no plausible mechanistic link between ivermectin’s antiparasitic action and antifungal efficacy against Candida. Evidence is insufficient (L5) to justify further evaluation at this time.

To proceed, the following is needed:

Local (Danish/EMA) product labelling data — warnings, contraindications, and drug interaction data are currently unavailable and block safety pre-assessment
Verified mechanism of action data for ivermectin
Preclinical or in vitro data demonstrating antifungal activity, if this indication is to be pursued further
Any emerging clinical trial or literature evidence specific to ivermectin in vulvovaginal candidiasis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.